Hexoskin, a Montreal-based digital health and AI company developing medical-grade wearables and algorithms for health monitoring and diagnostics, is very excited to announce today an additional USD $4.2M capital raise to invest in growth,…
Continue Reading
In the ever-changing landscape of healthcare technology, wearable gadgets could potentially prove to be a game changer in the area of neurological disorders, particularly those that present communication barriers. Consider a situation in which…
Continue Reading
Parkinson’s disease (PD) is a multifactorial neurodegenerative disorder with high prevalence among the elderly, primarily manifested by progressive decline in motor function. The aging global demographic and increased life expectancy have led to a…
Continue Reading
Digital biomarkers that remotely monitor symptoms have the potential to revolutionize outcome assessments in future disease-modifying trials in Parkinson’s disease (PD), by allowing objective and recurrent measurement of symptoms and signs collected in the…
Continue Reading
Wearable sensor technologies are becoming increasingly relevant in health research, particularly in the context of chronic disease management. They generate real-time health data that can be translated into digital biomarkers, which can provide insights…
Continue Reading
Background: Postpartum depression (PPD) poses a significant maternal health challenge. The current approach to detecting PPD relies on in-person postpartum visits, which contributes to underdiagnosis. Furthermore, recognizing PPD symptoms can be challenging. Therefore, we…
Continue Reading
Background: Diagnostic delays in autism are common, with the time to diagnosis being up to 3 years from the onset of symptoms. Such delays have a proven detrimental effect on individuals and families going…
Continue Reading
Empatica receives US Food and Drug Administration (FDA) 510(k) clearance for two new digital biomarkers for its Empatica Health Monitoring Platform
What You Should Know:
– Empatica, a digital health and AI company, has obtained FDA…
Continue Reading
What You Should Know:
– 23andMe, a genetic health and biopharmaceutical company launched Health Action Plan, a new digital tool for 23andMe+ members that draws on results from genetic reports, health history survey data, as…
Continue Reading
